메뉴 건너뛰기




Volumn 25, Issue 1, 2010, Pages 54-60

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: A 4-year study

Author keywords

Adefovir dipivoxil; Adefovir resistance; Chronic hepatitis B; Combination therapy; Hepatitis B e antigen negative; Lamivudine; Lamivudine resistance

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

EID: 73449125140     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05952.x     Document Type: Article
Times cited : (34)

References (36)
  • 2
    • 0036902495 scopus 로고    scopus 로고
    • World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants
    • Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J.Viral Hepat. 2002 9 : 52 61.
    • (2002) J.Viral Hepat. , vol.9 , pp. 52-61
    • Funk, M.L.1    Rosenberg, D.M.2    Lok, A.S.3
  • 3
    • 33646369150 scopus 로고    scopus 로고
    • Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment
    • Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin. Liver Dis. 2006 26 : 130 141.
    • (2006) Semin. Liver Dis. , vol.26 , pp. 130-141
    • Hadziyannis, S.J.1    Papatheodoridis, G.V.2
  • 4
    • 0033012793 scopus 로고    scopus 로고
    • Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group
    • Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999 29 : 889 896.
    • (1999) Hepatology , vol.29 , pp. 889-896
    • Tassopoulos, N.C.1    Volpes, R.2    Pastore, G.3
  • 5
    • 0033802362 scopus 로고    scopus 로고
    • Long-term therapy of chronic hepatitis B with lamivudine
    • Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000 32 : 828 834.
    • (2000) Hepatology , vol.32 , pp. 828-834
    • Lau, D.T.1    Khokhar, M.F.2    Doo, E.3
  • 6
    • 19044393444 scopus 로고    scopus 로고
    • Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B
    • Nikolaidis N, Vassiliadis T, Giouleme O et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin. Transplant. 2005 19 : 321 326.
    • (2005) Clin. Transplant. , vol.19 , pp. 321-326
    • Nikolaidis, N.1    Vassiliadis, T.2    Giouleme, O.3
  • 7
    • 0033983646 scopus 로고    scopus 로고
    • Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
    • Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 2000 32 : 300 306.
    • (2000) J. Hepatol. , vol.32 , pp. 300-306
    • Santantonio, T.1    Mazzola, M.2    Iacovazzi, T.3    Miglietta, A.4    Guastadisegni, A.5    Pastore, G.6
  • 8
    • 34547425435 scopus 로고    scopus 로고
    • Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management
    • Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007 46 : 254 265.
    • (2007) Hepatology , vol.46 , pp. 254-265
    • Lok, A.S.1    Zoulim, F.2    Locarnini, S.3
  • 9
    • 33646445732 scopus 로고    scopus 로고
    • Long-term lamivudine therapy in patients with precore mutant HBV-related liver disease
    • Vassiliadis T, Patsiaoura K, Saveriadis A et al. Long-term lamivudine therapy in patients with precore mutant HBV-related liver disease. J. Hepatol. 2002 36 : 94.
    • (2002) J. Hepatol. , vol.36 , pp. 94
    • Vassiliadis, T.1    Patsiaoura, K.2    Saveriadis, A.3
  • 10
    • 4043178381 scopus 로고    scopus 로고
    • Four years of treatment with lamivudine: Clinical and virological evaluations in HBe antigen-negative chronic hepatitis B
    • Gaia S, Marzano A, Smedile A et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 2004 20 : 281 287.
    • (2004) Aliment. Pharmacol. Ther. , vol.20 , pp. 281-287
    • Gaia, S.1    Marzano, A.2    Smedile, A.3
  • 11
    • 0037221907 scopus 로고    scopus 로고
    • Histological outcome during long-term lamivudine therapy
    • Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 117.
    • (2003) Gastroenterology , vol.124 , pp. 105-117
    • Dienstag, J.L.1    Goldin, R.D.2    Heathcote, E.J.3
  • 12
    • 0036288645 scopus 로고    scopus 로고
    • Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease
    • Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002 36 : 219 226.
    • (2002) Hepatology , vol.36 , pp. 219-226
    • Papatheodoridis, G.V.1    Dimou, E.2    Laras, A.3    Papadimitropoulos, V.4    Hadziyannis, S.J.5
  • 14
    • 33646464721 scopus 로고    scopus 로고
    • Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B
    • Vassiliadis T, Patsiaoura K, Tziomalos K et al. Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J. Gastroenterol. 2006 12 : 2417 2422.
    • (2006) World J. Gastroenterol. , vol.12 , pp. 2417-2422
    • Vassiliadis, T.1    Patsiaoura, K.2    Tziomalos, K.3
  • 15
    • 26844500312 scopus 로고    scopus 로고
    • A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
    • Chang TT, Gish RG, Hadziyannis SJ et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005 129 : 1198 1209.
    • (2005) Gastroenterology , vol.129 , pp. 1198-1209
    • Chang, T.T.1    Gish, R.G.2    Hadziyannis, S.J.3
  • 16
    • 4344627233 scopus 로고    scopus 로고
    • Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
    • Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004 48 : 3498 3507.
    • (2004) Antimicrob. Agents Chemother. , vol.48 , pp. 3498-3507
    • Tenney, D.J.1    Levine, S.M.2    Rose, R.E.3
  • 17
    • 33846785216 scopus 로고    scopus 로고
    • Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient
    • Villet S, Ollivet A, Pichoud C et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 2007 46 : 531 538.
    • (2007) J. Hepatol. , vol.46 , pp. 531-538
    • Villet, S.1    Ollivet, A.2    Pichoud, C.3
  • 18
    • 32444438958 scopus 로고    scopus 로고
    • Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine
    • Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 : 1414 1419.
    • (2005) Hepatology , vol.42 , pp. 1414-1419
    • Lampertico, P.1    Vigano, M.2    Manenti, E.3    Iavarone, M.4    Lunghi, G.5    Colombo, M.6
  • 19
    • 35648982926 scopus 로고    scopus 로고
    • Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients
    • Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 : 1445 1451.
    • (2007) Gastroenterology , vol.133 , pp. 1445-1451
    • Lampertico, P.1    Vigano, M.2    Manenti, E.3    Iavarone, M.4    Sablon, E.5    Colombo, M.6
  • 20
    • 20144380179 scopus 로고    scopus 로고
    • Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B
    • Vassiliadis T, Nikolaidis N, Giouleme O et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 2005 21 : 531 537.
    • (2005) Aliment. Pharmacol. Ther. , vol.21 , pp. 531-537
    • Vassiliadis, T.1    Nikolaidis, N.2    Giouleme, O.3
  • 21
    • 37549047969 scopus 로고    scopus 로고
    • Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine
    • Manolakopoulos S, Bethanis S, Koutsounas S et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment. Pharmacol. Ther. 2008 27 : 266 273.
    • (2008) Aliment. Pharmacol. Ther. , vol.27 , pp. 266-273
    • Manolakopoulos, S.1    Bethanis, S.2    Koutsounas, S.3
  • 22
    • 33847709539 scopus 로고    scopus 로고
    • Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B
    • Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 313.
    • (2007) Hepatology , vol.45 , pp. 307-313
    • Rapti, I.1    Dimou, E.2    Mitsoula, P.3    Hadziyannis, S.J.4
  • 23
    • 33644804410 scopus 로고    scopus 로고
    • Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients
    • Nikolaidis NL, Giouleme OI, Tziomalos KA et al. Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients. J. Gastroenterol. Hepatol. 2005 20 : 1721 1725.
    • (2005) J. Gastroenterol. Hepatol. , vol.20 , pp. 1721-1725
    • Nikolaidis, N.L.1    Giouleme, O.I.2    Tziomalos, K.A.3
  • 24
    • 34548543638 scopus 로고    scopus 로고
    • Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B
    • Vassiliadis T, Tziomalos K, Patsiaoura K et al. Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J. Gastroenterol. Hepatol. 2007 22 : 1582 1588.
    • (2007) J. Gastroenterol. Hepatol. , vol.22 , pp. 1582-1588
    • Vassiliadis, T.1    Tziomalos, K.2    Patsiaoura, K.3
  • 25
    • 34247194561 scopus 로고    scopus 로고
    • Management of hepatitis B: Summary of a clinical research workshop
    • Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007 45 : 1056 1075.
    • (2007) Hepatology , vol.45 , pp. 1056-1075
    • Hoofnagle, J.H.1    Doo, E.2    Liang, T.J.3    Fleischer, R.4    Lok, A.S.5
  • 26
    • 33847701354 scopus 로고    scopus 로고
    • Chronic hepatitis B
    • Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
    • (2007) Hepatology , vol.45 , pp. 507-539
    • Lok, A.S.1    McMahon, B.J.2
  • 27
    • 34547399523 scopus 로고    scopus 로고
    • Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients
    • Buti M, Elefsiniotis I, Jardi R et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J. Hepatol. 2007 47 : 366 372.
    • (2007) J. Hepatol. , vol.47 , pp. 366-372
    • Buti, M.1    Elefsiniotis, I.2    Jardi, R.3
  • 28
    • 34047161559 scopus 로고    scopus 로고
    • Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B
    • Chan HL, Wong VW, Tse CH et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment. Pharmacol. Ther. 2007 25 : 891 898.
    • (2007) Aliment. Pharmacol. Ther. , vol.25 , pp. 891-898
    • Chan, H.L.1    Wong, V.W.2    Tse, C.H.3
  • 29
    • 0041853784 scopus 로고    scopus 로고
    • Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
    • Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003 125 : 292 297.
    • (2003) Gastroenterology , vol.125 , pp. 292-297
    • Angus, P.1    Vaughan, R.2    Xiong, S.3
  • 30
    • 30344449469 scopus 로고    scopus 로고
    • Virologic response and resistance to adefovir in patients with chronic hepatitis B
    • Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006 44 : 283 290.
    • (2006) J. Hepatol. , vol.44 , pp. 283-290
    • Fung, S.K.1    Chae, H.B.2    Fontana, R.J.3
  • 31
    • 34247197017 scopus 로고    scopus 로고
    • Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients
    • Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Hepatology 2006 44 : 548A.
    • (2006) Hepatology , vol.44
    • Marcellin, P.1    Chang, T.T.2    Lim, S.G.3
  • 32
    • 33845671388 scopus 로고    scopus 로고
    • Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    • Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 1751.
    • (2006) Gastroenterology , vol.131 , pp. 1743-1751
    • Hadziyannis, S.J.1    Tassopoulos, N.C.2    Heathcote, E.J.3
  • 33
    • 27744510332 scopus 로고    scopus 로고
    • Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
    • Fung SK, Andreone P, Han SH et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 2005 43 : 937 943.
    • (2005) J. Hepatol. , vol.43 , pp. 937-943
    • Fung, S.K.1    Andreone, P.2    Han, S.H.3
  • 34
    • 34147121932 scopus 로고    scopus 로고
    • Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance
    • Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. J. Hepatol. 2007 46 : 756 758.
    • (2007) J. Hepatol. , vol.46 , pp. 756-758
    • Brunetto, M.R.1
  • 36
    • 34047267628 scopus 로고    scopus 로고
    • Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily
    • Hezode C, Chevaliez S, Bouvier-Alias M et al. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J. Hepatol. 2007 46 : 791 796.
    • (2007) J. Hepatol. , vol.46 , pp. 791-796
    • Hezode, C.1    Chevaliez, S.2    Bouvier-Alias, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.